| Literature DB >> 34900147 |
Ige Francis Olaoye1, Babatunde Joseph Oso1, Adepeju Aberuagba2.
Abstract
BACKGROUND: A large body of literature suggests that the extracts of Ocimum gratissimum (O. gratissimum) and Thymus vulgaris (T. vulgaris) play protective roles against various inflammatory disorders. However, the possible mechanism of action with reference to the interactions of their respective phytochemical compositions with pro-inflammatory mediators as the indication of their therapeutic effects is less clear. Therefore, the immunomodulatory properties of O. gratissimum and T. vulgaris were investigated in this study.Entities:
Keywords: Anti-inflammatory agents; Lipoxygenase; Ocimum; Phytochemicals; Plant extracts; Thymus plant
Year: 2021 PMID: 34900147 PMCID: PMC8606109
Source DB: PubMed Journal: Avicenna J Med Biotechnol ISSN: 2008-2835
Figure 1.Lipoxygenase inhibitory potentials of O. gratissimum and T. vulgaris comparable to indomethacin.
Molecular interactions of some selected phytochemical components of T. vulgaris and O. gratissimum with lipoxygenase
|
|
|
|
| |
|---|---|---|---|---|
|
| ||||
| Caryophyllene oxide | 2039864 | −6.50±0.06 | Phe352 | |
| Cis-ocimene | 1531619 | −4.93±0.03 | Val190, Leu194, Phe352, His360, Leu361, Ile593, Leu597 | |
| Eugenol | 1411 | −6.10±0.39 | Leu227, Tyr230, Gly309, Lys310, Gln509, Trp647 | |
|
| ||||
| Cymene | 968246 | −5.43±0.15 | Val190, His360, Leu361, His365 | |
| Terpinene | 967594 | −5.37±0.15 | Val190, His360 | |
| Thymol | 967597 | −5.47±0.20 | Val190, Glu356, His360, His365, Leu597 | |
|
| ||||
| - | 601283 | −7.70±0.06 | Leu178, Ala433, Ala434, Gln435, Leu447, Leu453, Pro456, Ala461, His462, Leu465, Leu507, Cys508, Asp512, Arg641 | |
Values with different superscripts are significantly different at p<0.05.
Figure 2.3D illustration of the molecular interactions of (i) caryophyllene oxide, (ii) cymene, (iii) eugenol, (iv) cis-ocimene, (v) terpinene, (vi) thymol, and (vi) indomethacin with lipoxygenase.
Solubility characteristics of the selected phytocompounds
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|
|
| ||||||
| Log Po/w (iLOGP) | 3.10 | 2.51 | 2.37 | 2.80 | 2.73 | 2.32 |
| Log Po/w (XLOGP3) | 3.56 | 4.10 | 2.27 | 4.26 | 4.50 | 3.30 |
| Log Po/w (WLOGP) | 3.94 | 3.12 | 2.13 | 3.48 | 3.31 | 2.82 |
| Log Po/w (MLOGP) | 3.67 | 4.47 | 2.01 | 3.56 | 3.27 | 2.76 |
| Log Po/w (SILICOS-IT) | 4.07 | 3.29 | 2.48 | 2.88 | 2.95 | 2.79 |
| Consensus Log Po/w | 3.67 | 3.50 | 2.25 | 3.40 | 3.35 | 2.80 |
|
| ||||||
| Log S (ESOL) | −3.450 | −3.630 | −2.460 | −3.170 | −3.450 | −3.190 |
| Solubility ( | 0.078 | 0.031 | 0.569 | 0.092 | 0.048 | 0.097 |
| Class | Soluble | Soluble | Soluble | Soluble | Soluble | Soluble |
| Log S (Ali) | −3.510 | −3.810 | −2.530 | −3.970 | −4.220 | −3.400 |
| Solubility ( | 0.068 | 0.021 | 0.490 | 0.015 | 0.008 | 0.060 |
| Class | Soluble | Soluble | Soluble | Soluble | Insoluble | Soluble |
| Log S (SILICOS-IT) | −3.510 | −3.570 | −2.790 | −2.040 | −2.230 | −3.010 |
| Solubility ( | 0.068 | 0.036 | 0.265 | 1.240 | 0.806 | 0.146 |
| Class | Soluble | Soluble | Soluble | Soluble | Soluble | Soluble |
The pharmacokinetics properties of the selected compounds
|
|
|
|
|
|
| |
|---|---|---|---|---|---|---|
|
| ||||||
| GI absorption | High | Low | High | Low | Low | High |
| BBB permeant | Yes | Yes | Yes | Yes | Yes | Yes |
| P-gp substrate | No | No | No | No | No | No |
| CYP1A2 inhibitor | No | No | Yes | No | No | Yes |
| CYP2C19 inhibitor | Yes | No | No | No | No | No |
| CYP2C9 inhibitor | Yes | No | No | No | No | No |
| CYP2D6 inhibitor | No | Yes | No | No | No | No |
| CYP3A4 inhibitor | No | No | No | No | No | No |
| Log Kp ( | −5.12 | −4.21 | −5.69 | −4.11 | −3.94 | −4.87 |
|
| ||||||
| Lipinski | Yes | Yes | Yes | Yes | Yes | Yes |
| Ghose | Yes | No | Yes | No | No | No |
| Veber | Yes | Yes | Yes | Yes | Yes | Yes |
| Egan | Yes | Yes | Yes | Yes | Yes | Yes |
| Muegge | No | No | No | No | No | No |
| Bioavailability score | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 | 0.55 |
Skin permeation.
Figure 3.Suitable physicochemical space for oral bioavailability of (i) caryophyllene oxide, (ii) cymene, (iii) eugenol, (iv) cis-ocimene, (v) terpinene, and (vi) thymol.
Molecular interactions of some selected phytochemical components of T. vulgaris and O. gratissimum with pro-inflammatory cytokines
|
|
|
|
|
|
|---|---|---|---|---|
|
| ||||
| Caryophyllene oxide | 2039864 | −5.45±0.05 | Leu113, Ser125, Phe128, Pro129, Gly130, Phe132 | |
| Cymene | 968246 | −4.85±0.05 | Leu113, Glu124, Pro129, Gly130, Phe132 | |
| Eugenol | 1411 | −4.80±0.00 | Leu113, Tyr111, Glu124, Pro129, Gly130 | |
| Cis-ocimene | 1531619 | −3.70±0.00 | Glu124, Pro129, Gly130, Phe132 | |
| Terpinene | 967594 | −4.45±0.05 | Glu124, Pro129, Gly130, Phe132 | |
| Thymol | 967597 | −4.80±0.01 | Leu113, Glu124, Pro129, Phe132 | |
|
| ||||
| Caryophyllene oxide | 2039864 | −5.50±0.00 | Glu23, Ile25, Asp26, Lys27, Arg182 | |
| Cymene | 968246 | −4.43±0.03 | Leu19, Ser22, Glu23, Asp26, Lys27 | |
| Eugenol | 1411 | −4.77±0.03 | Val96, Pro141, Ala145, Leu148 | |
| Cis-ocimene | 1531619 | −3.80±0.00 | Val96, Ala145, Leu148, | |
| Terpinene | 967594 | −4.20±0.06 | Lys27, Tyr31, Val96 | |
| Thymol | 967597 | −4.70±0.10 | Leu92, Glu95 | |
|
| ||||
| Caryophyllene oxide | 2039864 | −5.15±0.15 | Phe74, Ile103, Ser105, Gln107, Val112, Leu114, Ala138, Phe139, Gln140, Leu141, Phe169 | |
| Cymene | 968246 | −4.80±0.00 | Ala30, Phe169 | |
| Eugenol | 1411 | −4.35±0.05 | Ala30, His32, Phe53, Tyr76, Phe169 | |
| Cis-ocimene | 1531619 | −3.80±0.00 | Ala30, Tyr76, Phe169 | |
| Terpinene | 967594 | −4.15±0.05 | Ala30, His32, Phe53, Phe169 | |
| Thymol | 967597 | −4.55±0.05 | Ala30, Tyr76, Phe169 | |
|
| ||||
| Caryophyllene oxide | 2039864 | −5.10±0.10 | His16 | |
| Cymene | 968246 | −5.55±0.05 | His16 | |
| Eugenol | 1411 | −5.55±0.05 | His16 | |
| Cis-ocimene | 1531619 | −5.10±0.10 | His16 | |
| Terpinene | 967594 | −5.05±0.05 | His16 | |
| Thymol | 967597 | −5.30±0.10 | His16, Lys62 | |
|
| ||||
| Caryophyllene oxide | 2039864 | −4.60±0.10 | Ile20, Ser21, Asp62, Trp59, Ser63 | |
| Cymene | 968246 | −5.60±0.20 | Ile20, Val22, Leu25, Ala53, Trp59, Val60 | |
| Eugenol | 1411 | −5.45±0.25 | Ile20, Leu25, Ser27, Phe43, Ile51, Ala53, Val60, Ser63, Leu67 | |
| Cis-ocimene | 1531619 | −4.70±0.00 | Ile20, Arg24, Leu25, Ile51, Trp59 | |
| Terpinene | 967594 | −4.80±0.10 | Leu25, Ala53, Trp59, Val60 | |
| Thymol | 967597 | −5.05±0.05 | Thr16, Il20, Arg24, Thr45, Val47, Ile51, Trp59 | |
Values with different superscripts are significantly different at p<0.05.
Figure 4.3D illustration of the molecular interactions of (i) caryophyllene oxide, (ii) cymene, (iii) eugenol, (iv) cis-ocimene, (v) terpinene, and (vi) thymol with, A) IL-1, B) IL-6, C) TNF-α, D) IL-8, and E) CCL-2.
Figure 5.Molecular dynamics simulation of (i) IL-1, (ii) IL-6, (iii) TNF-α, (iv) IL-8, and (v) CCL-2 showing the, A) Deformability, B) B-factor, C) Eigenvalues, D) Variance, E) Covariance map, and F) Elastic network.